Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder.

Tzang RF, Wang YC, Yeh CB, Hsu CD, Liang HY, Yang PC, Liu HJ, Huang YS, Cheng H, Hsu YC, Liu SI, Pan CH, Huang YF, Huang CF, Wu YY, Huang YH, Liu HC, Chang HL.

Psychiatry Clin Neurosci. 2012 Feb;66(1):53-63. doi: 10.1111/j.1440-1819.2011.02289.x.

2.

Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.

Chou WJ, Chen SJ, Chen YS, Liang HY, Lin CC, Tang CS, Huang YS, Yeh CB, Chou MC, Lin DY, Hou PH, Wu YY, Liu HJ, Huang YF, Hwang KL, Chan CH, Pan CH, Chang HL, Huang CF, Hsu JW.

J Child Adolesc Psychopharmacol. 2012 Jun;22(3):215-25. doi: 10.1089/cap.2011.0006.

3.
4.

Prospective, naturalistic study of open-label OROS methylphenidate treatment in Chinese school-aged children with attention-deficit/hyperactivity disorder.

Zheng Y, Wang YF, Qin J, Wang LW, Zou LP, Jin XM, Xu T, Wang Y, Qi YL, Gong ME, Yin QY, Mai JN, Jing J, Luo XY, Ma HW, Li HB, Xie L, Li Y, Kuang GF, Yi MJ, Wang F, Zhu XH, Yao YB.

Chin Med J (Engl). 2011 Oct;124(20):3269-74.

5.

Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.

Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.

Psychiatry Clin Neurosci. 2009 Apr;63(2):167-75. doi: 10.1111/j.1440-1819.2009.01937.x.

6.

Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.

Kordon A, Stollhoff K, Niederkirchner K, Mattejat F, Rettig K, Schäuble B.

Postgrad Med. 2011 Sep;123(5):27-38. doi: 10.3810/pgm.2011.09.2457.

PMID:
21904084
7.

[Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children].

Pan XX, Ma HW, Wan B, Dai XM.

Zhongguo Dang Dai Er Ke Za Zhi. 2008 Aug;10(4):471-4. Chinese.

PMID:
18706164
8.

Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.

Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Slawik L, Schäuble B.

Curr Med Res Opin. 2011;27 Suppl 2:35-44. doi: 10.1185/03007995.2011.601733.

PMID:
21787126
9.

Remission Rate and Functional Outcomes During a 6-Month Treatment With Osmotic-Release Oral-System Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder.

Su Y, Li H, Chen Y, Fang F, Xu T, Lu H, Xie L, Zhuo J, Qu J, Yang L, Wang Y.

J Clin Psychopharmacol. 2015 Oct;35(5):525-34. doi: 10.1097/JCP.0000000000000389.

PMID:
26267421
10.

Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.

Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gómez N, Yelmo S, Ferrer M, Martínez Y, Casas M.

CNS Drugs. 2008;22(7):603-11.

PMID:
18547128
11.

National survey of adherence, efficacy, and side effects of methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.

Gau SS, Chen SJ, Chou WJ, Cheng H, Tang CS, Chang HL, Tzang RF, Wu YY, Huang YF, Chou MC, Liang HY, Hsu YC, Lu HH, Huang YS.

J Clin Psychiatry. 2008 Jan;69(1):131-40.

PMID:
18312048
12.

Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD.

Abikoff H, Nissley-Tsiopinis J, Gallagher R, Zambenedetti M, Seyffert M, Boorady R, McCarthy J.

J Am Acad Child Adolesc Psychiatry. 2009 Feb;48(2):166-75. doi: 10.1097/CHI.0b013e3181930626.

PMID:
19127171
14.

Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.

Niederkirchner K, Slawik L, Wermelskirchen D, Rettig K, Schäuble B.

Expert Rev Neurother. 2011 Apr;11(4):499-508. doi: 10.1586/ern.11.18.

PMID:
21469923
15.

Switching from methylphenidate immediate release to MPH-SODAS in attention-deficit/hyperactivity disorder.

Maia CR, Matte BC, Ludwig HT, Rohde LA.

Eur Child Adolesc Psychiatry. 2008 Apr;17(3):133-42.

PMID:
17846812
17.

A comparison of once-daily extended-release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study).

Swanson JM, Wigal SB, Wigal T, Sonuga-Barke E, Greenhill LL, Biederman J, Kollins S, Nguyen AS, DeCory HH, Hirshe Dirksen SJ, Hatch SJ; COMACS Study Group..

Pediatrics. 2004 Mar;113(3 Pt 1):e206-16.

PMID:
14993578
18.

Norepinephrine transporter -3081(A/T) and alpha-2A-adrenergic receptor MspI polymorphisms are associated with cardiovascular side effects of OROS-methylphenidate treatment.

Cho SC, Kim BN, Cummins TD, Kim JW, Bellgrove MA.

J Psychopharmacol. 2012 Mar;26(3):380-9. doi: 10.1177/0269881111405356.

PMID:
21628343
19.

Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings.

Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD.

Pediatrics. 2001 Jun;107(6):E105.

PMID:
11389303
Items per page

Supplemental Content

Support Center